Buscar en
Revista Española de Cirugía Ortopédica y Traumatología (English Edition)
Toda la web
Inicio Revista Española de Cirugía Ortopédica y Traumatología (English Edition) Treatment of Posttraumatic Osteomyelitis with Oral Linezolid
Journal Information
Vol. 51. Issue 2.
Pages 75-79 (March - April 2007)
Share
Share
Download PDF
More article options
Vol. 51. Issue 2.
Pages 75-79 (March - April 2007)
Original papers
Full text access
Treatment of Posttraumatic Osteomyelitis with Oral Linezolid
Tratamiento con linezolid oral en osteomielitis postraumáticas
Visits
1199
F.J. Romero-Candaua,
Corresponding author
fernando_romero@fremap.es

Corresponding author: Unidad de Infecciones Óseas y Articulares. Hospital FREMAP. Avda. Jerez s/n. 41012 Sevilla.
, R. Pérez-Ferrib, J.M. Madrigalc, F. Najarroc, F. Santosc, F. Huesad
a Internal Medicine. Bone and Joint Infection Unit. FREMAP Hospital. Seville
b Clinical Test Laboratory. Bone and Joint Infection Unit. FREMAP Hospital. Seville
c Trauma Surgery. Bone and Joint Infection Unit. FREMAP Hospital. Seville
d Rehabilitation. Bone and Joint Infection Unit. FREMAP Hospital. Seville
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Purpose

To assess the efficacy and safety of oral linezolid associated with surgery in the treatment of posttraumatic osteomyelitis.

Materials and methods

Monitored prospective study of all patients suffering from posttraumatic osteomyelitis caused by Methicillin-resistant Gram positive cocci treated with elective surgery and linezolid 600 mg every 12 hours from June 2002 to December 2004.

Results

We have used linezolid to treat 9 patients with posttraumatic osteomyelitis. The microorganisms isolated were: Methicillin-resistant Staphylococcus aureus, 1; Methicillin-resistant Staphylococcus epidermidis, 7. Two patients had an associated infection caused by Pseudomonas aeruginosa. Mean duration of treatment was 9.5 weeks (range 6-12). During follow-up 8 patients were found to be clinically cured with fracture stabilization and with no sign of infection. One patient had an infected mal-union. Linezolid was excellently tolerated and in none of the cases it was necessary to discontinue administration due to toxicity.

Conclusions

In our experience oral linezolid associated with surgery can be an excellent option for the treatment of posttraumatic osteomyelitis caused by Methicillin-resistant Gram positive bacteria that do not respond to other antimicrobials or if these are not well tolerated.

Key words:
posttraumatic osteomyelitis
linezolid
Methicillin-resistant Staphylococcus
Objetivo

Valorar la eficacia y seguridad de linezolid oral asociado a cirugía en el tratamiento de las osteomielitis postraumáticas.

Material y método

Estudio prospectivo monitorizado de todos los pacientes ingresados en la unidad de infecciones óseas y articulares del hospital con osteomielitis postraumática por cocos grampositivos meticilín resistentes tratados con cirugía programada y linezolid, 600 mg cada doce horas, desde junio de 2002 hasta diciembre de 2004.

Resultados

Hemos tratado con linezolid a nueve pacientes con osteomielitis postraumática. Los microorganismos aislados han sido: un Staphylococcus aureus meticilín resistente, un estafilococo coagulasa negativo meticilín resistente, siete Staphylococcus epidermidis meticilín resistentes. Dos pacientes han tenido infección asociada con Pseudomonas aeruginosa. La duración media del tratamiento ha sido de 9,5 semanas (rango 6-12). En el seguimiento realizado ocho pacientes están clínicamente curados con estabilización de la fractura y sin signos de infección. Un paciente está en situación de pseudoartrosis infectada. El linezolid ha sido tolerado de manera excelente y no ha habido necesidad de suspender la medicación por toxicidad en ningún caso.

Conclusiones

En nuestra experiencia, linezolid oral asociado a cirugía puede ser una excelente opción de tratamiento en osteomielitis postraumática causada por bacterias grampositivas resistentes a meticilina que no respondan a la administración de otros antimicrobianos o que no toleren éstos.

Palabras clave:
osteomielitis postraumática
linezolid
Staphylococcus meticilín resistentes
Full text is only aviable in PDF
References
[1.]
D. Fernández-Yruegas.
Tratamiento de la osteomielitis crónica.
Rev Ortop Traumatol, 48 (2004), pp. 4-11
[2.]
K.W. Klemm.
Treatment of infected pseudoarthrosis of the femur and tibia with interlocking nail.
Clin Orthop, 212 (1986), pp. 174-184
[3.]
G. Cierny III.
Infected Tibial Nonunions.
Clin Orthop, 360 (1999), pp. 97-105
[4.]
J.T. Mader, J. Wang, J.H. Calhoun.
Antibiotic therapy for musculoskeletal infections.
J Bone Joint Surg Am, 83 (2001), pp. 1878-1890
[5.]
W.S. Champney, M. Miller.
Linezolid is an especific inhibitor of 50S ribosomal subunit formation in Staphylococcus aureus cells.
Curr Microbiol, 44 (2002), pp. 350-356
[6.]
J.G. Slatter, D.J. Stalker, K.L. Feenstra, I.R. Welshman, J.B. Bruss, J.P. Sams, et al.
Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of linezolid to healthy human subjects.
Drug Metab Dispos, 29 (2001), pp. 1136-1145
[7.]
A.M. Lovering, J. Zhang, G.C. Bannister, B.J.A. Lankester, J.H.M. Brown, G. Narendra, et al.
Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement.
J Antimicrob Chemother, 50 (2002), pp. 73-77
[8.]
B. Rana, I. Butcher, P. Grigoris, C. Murnaghan, R.A. Seaton, C.M. Tobin.
Linezolid penetration into osteo-articular tissues.
J Antimicrob Chemother, 50 (2002), pp. 747-750
[9.]
F. Kutscha-Lissberg, U. Hebler, G. Muhr, M. Köller.
Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci.
Antimicrobial Agents Chemother, 47 (2003), pp. 3964-3966
[10.]
J.W. Chien, M.L. Kucia, R.A. Salata.
Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.
Clin Infect Dis, 30 (2000), pp. 146-151
[11.]
E. Rubinstein, S. Cammarata, T. Oliphant, R. Wunderink, Linezolid Nosocomial Pneumonia Study Group.
Linezolid versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized; doble-blind, multicenter study.
Clin Infect Dis, 32 (2001), pp. 402-412
[12.]
M. Melzer, D. Goldsmith, W. Gransden.
Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteriemias.
Clin Infect Dis, 31 (2000), pp. 208-209
[13.]
M. Till, R.L. Wixson, P.E. Pertel.
Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium.
Clin Infect Dis, 34 (2002), pp. 1412-1414
[14.]
C.R. Rayner, L.M. Baddour, M.C. Birminghan, C. Norden, A.K. Meagher, J.J. Schentag.
Linezolid in the treatment of osteomyelitis: results of compassionate use experience.
Infection, 32 (2004), pp. 8-14
[15.]
N. Rao, B.H. Ziran, R.A. Hall, E.R. Santa.
Successful treatment of chronic bone and joint infections with oral linezolid.
Clin Orthop, 427 (2004), pp. 67-71
[16.]
R.R. Razonable, D.R. Osmon, J.M. Steckelberg.
Linezolid Therapy for Orthopedic Infections.
Mayo Clin Proc, 79 (2004), pp. 1137-1144
[17.]
M. Bassetti, F. Vitale, G. Melica, E. Righi, A. Di Biagio, L. Molfetta, et al.
Linezolid in the treatment of Gram-positive prosthetic joint infections.
J Antimicrob Chemother, 55 (2005), pp. 387-390
Copyright © 2007. Sociedad Española de Cirugía Ortopédica y Traumatología (SECOT). All rights reserved
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos